Contact Us
Search:
Our CompanyPartnershipsProductsContract ManufacturingInvestor Relations

    Akorn News

05.03.2010 Akorn Reports First Quarter 2010 Financial Results; Achieves Positive Operating Income from Strong Demand in Core Business; Raises Outlook for 2010
04.21.2010 Akorn Announces FDA Approval to Re-Launch Erythromycin Ophthalmic Ointment USP 3.5 g
04.19.2010 Akorn, Inc. Announces First Quarter 2010 Earnings Release and Conference Call Information
04.15.2010 Akorn, Inc. Announces FDA Approval for Hydromorphone Hydrochloride Injection 10mg/mL in 1mL, 5mL and 50mL Doses
03.15.2010 Akorn Reports 2009 Fourth Quarter and Year-End Financial Results; Achieves Positive Fourth Quarter Cash Flow and Adjusted EBITDA; Refocuses R&D efforts to Strengthen New Product Pipeline
03.11.2010 Akorn, Inc. Enters into an Agreement to Sell Common Stock and Warrants
02.09.2010 Akorn, Inc. Announces Fourth Quarter 2009 Earnings Release and Conference Call Information
11.10.2009 Akorn Reports Third Quarter 2009 Financial Results; Launches Two New Products: Ketorolac Tromethamine Ophthalmic and Hydralazine HCL
10.27.2009 Akorn, Inc. Announces Third Quarter 2009 Earnings Release and Conference Call Information
08.11.2009 Akorn Reports Second Quarter 2009 Financial Results
07.29.2009 Akorn, Inc. Announces Second Quarter 2009 Earnings Release and Conference Call Information
06.17.2009 Akorn Acquires Capastat® Sulfate from Eli Lilly and Company
06.09.2009 Akorn Announces Management Changes
05.12.2009 Akorn Reports First Quarter 2009 Financial Results
04.01.2009 Akorn Issues Important Business Updates:
-- Purchase of Existing Credit Facility --
-- Renegotiation of Distribution Agreement --
03.30.2009 Akorn Appoints Jeffrey A. Whitnell as Interim Chief Executive Officer
03.02.2009 Akorn Appoints Raj Rai as Strategic Consultant
02.25.2009 Akorn Amplifies Form 8-K Disclosure
01.29.2009 Akorn Announces Management Change

© Akorn, Inc. Lake Forest, Illinois, USA.

This web site is intended for informational purposes only and not intended to replace discussion with a healthcare provider.

If you have any questions regarding the content of this site please contact Akorn.